GlassScriptPhysician profile
Ellen Zhuravsky
NPI 1356671671
$5,933.03
in general payments reported to CMS, 2019-2025
25 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2022: $1,270 · 2023: $1,235 · 2024: $1,699 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,267.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,458.22 | 2021-2025 | |
| Glaxosmithkline, LLC. | $679.22 | 2021-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $602.24 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Sumitomo Pharma America, INC. | $507.01 | 2023-2025 | Gemtesa |
| Amgen INC. | $446.35 | 2021-2024 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $433.50 | 2022-2024 | Trulance, Xifaxan |
| Urovant Sciences INC | $312.44 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $195.53 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $160.54 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $157.41 | 2023-2025 | |
| Lilly USA, LLC | $155.90 | 2022-2024 | Mounjaro, Jardiance |
| Biohaven Pharmaceuticals, INC. | $139.47 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $93.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.45 | 2022-2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $68.70 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $67.60 | 2022-2024 | Ztlido |
| Phathom Pharmaceuticals, INC. | $64.15 | 2024 | Voquezna |
| Shield Therapeutics INC | $63.59 | 2024-2025 | |
| Axsome Therapeutics, INC. | $53.99 | 2025 | Symbravo |
| Novartis Pharmaceuticals Corporation | $49.76 | 2024 | |
| Horizon Therapeutics Plc | $39.41 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.44 | 2023 | |
| Verona Pharma, INC. | $26.06 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $23.77 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $20.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Zhuravsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.